分布成本效益分析走向成熟。 - Suppr

Suppr

超能文献

Distributional Cost-Effectiveness Analysis Comes of Age.

作者信息

Cookson Richard, Griffin Susan, Norheim Ole F, Culyer Anthony J, Chalkidou Kalipso

机构信息

Centre for Health Economics, University of York, York, England, UK.

出版信息

Value Health. 2021 Jan;24(1):118-120. doi: 10.1016/j.jval.2020.10.001. Epub 2020 Nov 7.

DOI:10.1016/j.jval.2020.10.001

PMID:33431145

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7813213/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cedd/7813213/b4c007fbcde1/gr1.jpg

相似文献

Distributional Cost-Effectiveness Analysis Comes of Age.

Value Health. 2021 Jan;24(1):118-120. doi: 10.1016/j.jval.2020.10.001. Epub 2020 Nov 7.

Medical electronics: buy now.

Med Device Technol. 2003 Jun;14(5):37.

The need for independent physics advice.

Eur J Nucl Med Mol Imaging. 2003 Apr;30(4):491-3. doi: 10.1007/s00259-003-1122-4.

Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.

Health Technol Assess. 2015 Feb;19(14):1-503, v-vi. doi: 10.3310/hta19140.

Equity in national healthcare economic evaluation guidelines: Essential or extraneous?

Soc Sci Med. 2024 Sep;357:117220. doi: 10.1016/j.socscimed.2024.117220. Epub 2024 Aug 13.

NICE, social values, and balancing objectivity and equity.

Pharmacoeconomics. 2014 Nov;32(11):1039-41. doi: 10.1007/s40273-014-0220-4.

Objectivity and equity: clarity required. A response to Hill and Olson.

Pharmacoeconomics. 2014 Dec;32(12):1249-50. doi: 10.1007/s40273-014-0239-6.

Recent amendments to NICE's value-based assessment of health technologies: implicitly inequitable?

Expert Rev Pharmacoecon Outcomes Res. 2017 Jun;17(3):239-242. doi: 10.1080/14737167.2017.1330152. Epub 2017 May 23.

Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project.

Health Technol Assess. 2013 Dec;17(58):v-vi, 1-192. doi: 10.3310/hta17580.

Methodological issues in undertaking independent cost-effectiveness analysis for NICE: the case of therapies for ADHD.

Eur J Health Econ. 2008 May;9(2):137-45. doi: 10.1007/s10198-007-0052-7. Epub 2007 May 3.

引用本文的文献

Stakeholders' Perceptions of the Nature-Based Healing Industry in South Korea: A Q Methodology Study.

Healthcare (Basel). 2025 Aug 14;13(16):1990. doi: 10.3390/healthcare13161990.

The Impact of Alteplase Coverage on Health Equity for the Treatment of Ischemic Stroke in the USA: A Distributional Cost-Effectiveness Analysis.

Appl Health Econ Health Policy. 2025 Jul 1. doi: 10.1007/s40258-025-00985-6.

Using Linked Health Service Data in Multimodal Modeling of Kidney Transplant Waitlist Outcomes: Protocol for the Maximizing Organ Donor Utility Systemwide (MODUS) Study.

JMIR Res Protoc. 2025 Jul 29;14:e67588. doi: 10.2196/67588.

Protocol for the economic evaluation of the Care for Adolescents who Received Information 'Bout Outcomes, 2nd iteration (CARIBOU-2) non-randomised, cluster-controlled trial of an integrated care pathway for depression in adolescents.

BMJ Open. 2025 May 15;15(5):e092541. doi: 10.1136/bmjopen-2024-092541.

Application of distributional cost-effectiveness analysis methodology in real-world studies: a scoping review protocol.

BMJ Open. 2025 May 12;15(5):e099673. doi: 10.1136/bmjopen-2025-099673.

Distributional Cost-Effectiveness Analysis in Genomic Medicine: Considerations for Addressing Health Equity.

Value Health. 2025 May 6. doi: 10.1016/j.jval.2025.04.2162.

Policy models for preventative interventions in cardiometabolic diseases: a systematic review.

BMC Health Serv Res. 2025 May 2;25(1):635. doi: 10.1186/s12913-025-12781-y.

Social determinants of where people die: A study of moderators and mediators using linked UK Census and mortality data.

SSM Popul Health. 2025 Mar 21;30:101784. doi: 10.1016/j.ssmph.2025.101784. eCollection 2025 Jun.

Decision-Analytical Modelling of Medicines in the Middle East: A Systematic Review of Economic Evaluation Studies.

Appl Health Econ Health Policy. 2025 Apr 12. doi: 10.1007/s40258-024-00940-x.

Using natural experiments to evaluate population health and health system interventions: new framework for producers and users of evidence.

BMJ. 2025 Mar 28;388:e080505. doi: 10.1136/bmj-2024-080505.

本文引用的文献

COVID-19 Pandemic, Unemployment, and Civil Unrest: Underlying Deep Racial and Socioeconomic Divides.

JAMA. 2020 Jul 21;324(3):227-228. doi: 10.1001/jama.2020.11132.

To include or not include: renal dialysis policy in the era of universal health coverage.

BMJ. 2020 Jan 28;368:m82. doi: 10.1136/bmj.m82.

Aggregate Distributional Cost-Effectiveness Analysis of Health Technologies.

Value Health. 2019 May;22(5):518-526. doi: 10.1016/j.jval.2019.03.006.

Evaluation of Intervention Impact on Health Inequality for Resource Allocation.

Med Decis Making. 2019 Apr;39(3):171-182. doi: 10.1177/0272989X19829726. Epub 2019 Feb 28.

Distributional cost-effectiveness analysis in low- and middle-income countries: illustrative example of rotavirus vaccination in Ethiopia.

Health Policy Plan. 2018 Apr 1;33(3):456-463. doi: 10.1093/heapol/czx175.

CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials.

BMJ. 2017 Nov 23;359:j5085. doi: 10.1136/bmj.j5085.

Using Cost-Effectiveness Analysis to Address Health Equity Concerns.

Value Health. 2017 Feb;20(2):206-212. doi: 10.1016/j.jval.2016.11.027.

Extended Cost-Effectiveness Analysis for Health Policy Assessment: A Tutorial.

Pharmacoeconomics. 2016 Sep;34(9):913-23. doi: 10.1007/s40273-016-0414-z.

Cardiovascular screening to reduce the burden from cardiovascular disease: microsimulation study to quantify policy options.

BMJ. 2016 Jun 8;353:i2793. doi: 10.1136/bmj.i2793.

A new proposal for priority setting in Norway: Open and fair.

Health Policy. 2016 Mar;120(3):246-51. doi: 10.1016/j.healthpol.2016.01.012. Epub 2016 Jan 18.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验